Disclosure:

The reader/viewer should not assume that investments in the securities identified and discussed were or will be profitable and it should not be assumed that recommendations made in the future will be profitable.

   All information is provided for informational purposes only and should not be deemed as a recommendation to buy the securities mentioned. Cheviot closely monitors its positions and may make changes to the portfolio’s investment strategy when warranted by changing market conditions. If a security’s underlying fundamentals or valuation measures change, Cheviot will reevaluate its position and may sell part or all of its position. There can be no assurance that Cheviot’s clients will continue to hold the same position in companies described herein, and their portfolio positions may change at any time. Past performance is no guarantee of future results. All investments involve risk including the loss of principal.

 

The reader/viewer should not assume that investments in the securities identified and discussed were or will be profitable and it should not be assumed that recommendations made in the future will be profitable.
   All information is provided for informational purposes only and should not be deemed as a recommendation to buy the securities mentioned. Cheviot closely monitors its positions and may make changes to the portfolio’s investment strategy when warranted by changing market conditions. If a security’s underlying fundamentals or valuation measures change, Cheviot will reevaluate its position and may sell part or all of its position. There can be no assurance that Cheviot’s clients will continue to hold the same position in companies described herein, and their portfolio positions may change at any time. Past performance is no guarantee of future results. All investments involve risk including the loss of principal.

Veteran Investor Explains Warren Buffett’s Record $9 Billion in Buybacks and Discusses the Market’s Reaction to Pfizer’s Vaccine

As seen in : Business Insider

— November 10, 2020

By Theron Mohamed

Warren Buffett’s Berkshire Hathaway repurchased a record $9 billion of its stock in the third quarter. The surge in share buybacks likely reflects the famed investor’s failure to bag an “elephant-sized acquisition,” one of his longstanding shareholders told Business Insider.

“To know Buffett is to understand that he would prefer to make large investments in public company shares, or buy businesses in their entirety, instead of buying Berkshire’s own shares,” Darren Pollock, a portfolio manager at Cheviot Value Management, said in an email.

In other words, the Berkshire boss views repurchasing shares as an inferior use of funds compared to buying either a large chunk, or all, of a company. The reason is that businesses can rise in value, pay dividends, and generate cash for him to allocate across his conglomerate.

The billionaire investor may have allowed Berkshire’s cash pile to swell to a record $147 billion in the second quarter because he was hoping an elephant would enter his sights, as the pandemic ravaged markets, Pollock said. The buybacks last quarter suggest that didn’t happen.

“Buffett’s inability to find attractive, sizable, external acquisitions during and after the market’s swoon caused him to look inward,” he said.

On the bright side, the Berkshire chief repurchased his company’s shares at less than 1.2 times book value last quarter, Pollock said. Buffett has vowed in the past to aggressively buy Berkshire stock at that multiple or lower.

“As a shareholder, I’m very pleased to see him capitalizing on the market underpricing Berkshire’s shares,” Pollock said. Cheviot currently owns $52 million of Berkshire stock, and Buffett’s company has been its largest holding for more than 20 years.

Vaccines and value stocks

The news that Pfizer and BioNTech’s COVID-19 vaccine proved extremely effective in a late-stage trial sparked a massive stock-market rally on Monday, although some of the gains faded as investors realized the challenges ahead.

Pollock described the prospect of a working vaccine as “the largest step in the right direction that the medical community has made thus far to fight COVID.”

“Stay-at-home” stocks such as Zoom, Peloton, and Snap tumbled on Monday, while airlines, cruise lines, cinemas, theme parks, and other “real economy” stocks soared in value. Indeed, Berkshire gained as much as $35 billion in market value as the conglomerate’s stakes in Bank of America, Coca-Cola, and American Express soared in value.

“Today witnessed a great rotation out of those companies’ shares which did best the past several months under the view that a vaccine was far off in the distance, and into the beaten-down shares that will benefit the most from a reopening of society,” Pollock said.

The market reaction makes sense as widespread inoculation in a matter of months could revitalize many companies’ prospects, he continued.

Though hopeful himself, Pollock added, investors may have jumped the gun as “the vaccine’s production, distribution, and acceptance still have a long way to go – even without potential setbacks, something that is not uncommon in drug trials.”

Cheviot is a completely independent firm, focused on providing objective advice to clients – always with the highest of integrity and the priority of putting the client first in everything we do.

Account Access :

View your investment portfolio.

“Someone is sitting in the shade today because someone planted a tree a long time ago.”

— Warren Buffett

Contact:

Cheviot Value
Management, LLC

433 N. Camden Dr., Suite 800
Beverly Hills, CA 90210

310-451-8600